Pioneering science &
a visionary approach
O U R V I S I O N
Our mission is to get therapeutics to patients who currently have no effective treatment, so we’re meticulously working on aspects like optimized delivery to ensure efficacy. We deviate from traditional models of drug development by solely focusing on performing science that gives our drugs the best chance to succeed in clinical trials. We believe that while false positives may be costly, false negatives are moral failures when there are no other treatments available.
Novoron’s first-in-class pipeline of therapeutics
Novoron’s core technology allows us to dissect and precisely target specific components of individual receptors in an unprecedented fashion.
Our growing pipeline consists of various indication and receptor-specific compounds tailored to the ideal route of administration.
Novoron's core technology allows us to discover and develop molecules that, depending on the condition, avoid unwanted interactions either across the LDLR family of receptors, or within these receptors themselves. The latter point is critical, as this family can be quite large with multiple sites of important binding, disruption of which could possibly lead to unwanted consequences
ALZHEIMER’S & TAUOPATHIES
Tau is a naturally occurring protein in the brain. When too much is produced or altered, it can contribute to neurodegenerative diseases such as Alzheimer’s or chronic traumatic encephalopathy (CTE). One of the hallmarks of tauopathies is the spread of tau from parts of the brain with abnormal production to other brain regions.
Research into the causes of and effective treatments for tauopathies and Alzheimer’s has been ongoing for decades, with frustratingly few results. Recently, research has shown that LRP1 is a critical factor in the spread of tau. We’re currently working to develop molecules that stop the spread of tau in the brain.
SPINAL CORD INJURY (SCI)
Nerves damaged after a spinal cord injury attempt to regenerate, but are blocked from doing so by inhibitory molecules at the site of damage. We’ve developed a molecule that shuts down the signals that confuse neurons and suppress regeneration.
In animal models of injury, our approach promotes the growth of nerve cells and leads to significant recovery of motor function. We’re currently working to explore the therapeutic potential of our molecule and inform preclinical studies to set our drug up for success in clinical trials.